Compare BLKB & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | DMRA |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2004 | 2020 |
| Metric | BLKB | DMRA |
|---|---|---|
| Price | $41.89 | $28.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $50.00 | $43.00 |
| AVG Volume (30 Days) | ★ 673.6K | 501.3K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $62.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.58 | $16.50 |
| 52 Week High | $70.71 | $34.89 |
| Indicator | BLKB | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 80.48 | 51.17 |
| Support Level | $34.65 | $22.71 |
| Resistance Level | $64.76 | $34.89 |
| Average True Range (ATR) | 2.08 | 2.50 |
| MACD | 1.04 | -0.42 |
| Stochastic Oscillator | 97.23 | 27.91 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.